BIO-TECHNE Corp financials

TECH CIK 0000842023

Source: EDGAR filings · Built 2026-09-22T01:28:30Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Free Cash Flow 263.22M 256.55M 236.10M 216.15M 280.36M 307.86M
EBITDA 349.25M 212.16M 318.40M 406.18M 397.66M 325.04M
Working Capital 580.70M 432.45M 458.04M 492.97M 429.54M 358.32M
Net Debt 24.38M 281.87M 267.75M 274.39M 140.90M 208.96M
Gross Margin 65.77% 64.80% 66.41% 67.72% 68.42% 67.97%
Operating Margin 20.73% 8.38% 17.83% 26.30% 26.83% 25.49%
Net Margin 14.97% 6.02% 14.50% 25.10% 24.61% 15.08%
Return on Equity (ROE) 8.63% 3.83% 8.13% 14.51% 15.99% 8.98%
Return on Assets (ROA) 7.03% 2.87% 6.22% 10.81% 11.86% 6.20%
Current Ratio 4.55× 3.46× 3.87× 4.84× 3.44× 3.35×
Debt-to-Equity 0.14× 0.23× 0.20× 0.23× 0.18× 0.26×
Effective Tax Rate 24.44% 25.45% 9.47% 15.71% 12.70% 5.80%
Cash Conversion Ratio 1.61× 3.92× 1.78× 0.89× 1.20× 2.51×
Accruals Ratio -0.04× -0.08× -0.05× 0.01× -0.02× -0.09×
SBC % of Revenue 3.40% 3.35% 3.28% 3.45% 3.82% 5.26%
CapEx Coverage 10.12× 9.27× 4.75× 6.65× 7.24× 7.95×
Free Cash Flow Per Share $1.68 $1.61 $1.47 $1.34 $1.71 $1.90

Income Statement

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Revenue from Contract with Customer, Excluding Assessed Tax 1.22B 1.22B 1.16B 1.14B 1.11B 931.03M
Revenues 1.22B 1.22B 1.16B 1.14B — —
Cost of Goods and Services Sold 415.97M 429.36M 389.33M 366.89M 349.10M 298.18M
Gross Profit 799.07M 790.27M 769.73M 769.82M 756.50M 632.85M
Selling, General and Administrative Expense 452.42M 588.52M 466.38M 378.38M 372.77M 324.95M
Operating Expenses 547.18M 688.02M 563.04M 470.87M 459.91M 395.55M
Operating Income (Loss) 251.89M 102.25M 206.69M 298.94M 296.59M 237.30M
Income Tax Expense (Benefit) 58.82M 25.06M 17.58M 53.22M 38.29M 8.59M
Net Income (Loss) Attributable to Parent — 73.40M 168.10M 285.26M 272.05M 140.41M
Earnings Per Share, Basic $1.17 $0.47 $1.07 $1.81 $1.73 $0.91
Weighted Average Number of Shares Outstanding, Basic 155.96M 157.52M 157.71M 157.18M 156.87M 154.99M
Earnings Per Share, Diluted $1.16 $0.46 $1.05 $1.76 $1.66 $0.87
Weighted Average Number of Shares Outstanding, Diluted 157.01M 159.72M 160.77M 161.85M 164.11M 161.93M

Balance Sheet

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Cash and Cash Equivalents, at Carrying Value 264.71M 162.19M 151.79M 180.57M 172.57M 199.09M
Assets, Current 744.40M 608.30M 617.42M 621.48M 605.56M 510.61M
Assets 2.59B 2.56B 2.70B 2.64B 2.29B 2.26B
Liabilities, Current 163.70M 175.85M 159.38M 128.51M 176.02M 152.28M
Stockholders' Equity Attributable to Parent 2.11B 1.92B 2.07B 1.97B 1.70B 1.56B
Common Stock, Shares, Outstanding 156.10M 154.97M 158.22M 157.64M 156.64M 38.96M

Cash Flow Statement

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Net Cash Provided by (Used in) Operating Activities 292.07M 287.56M 298.98M 254.39M 325.27M 352.16M
Payments to Acquire Property, Plant, and Equipment 28.85M 31.01M 62.88M 38.24M 44.91M 44.30M
Net Cash Provided by (Used in) Investing Activities -18.19M -35.18M -203.03M -265.65M -96.85M -243.52M
Payments for Repurchase of Common Stock 41.67M 275.73M 80.04M 19.56M 160.95M 43.18M
Net Cash Provided by (Used in) Financing Activities -169.11M -253.91M -122.40M 22.62M -242.85M -62.55M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (TECH CIK 0000842023), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

LH

LABCORP HOLDINGS INC.

VEEV

Veeva Systems Inc.

CVS

CVS HEALTH CORPORATION